Table 3 Baseline characteristics of the sample of octogenarians by AF status
From: Atrial fibrillation incidence and outcomes in two cohorts of octogenarians: LiLACS NZ
No AF, n = 691 (col %) | Yes AF, n = 186 (col %) | |
|---|---|---|
Māori | 281 (41%) | 98 (53%)** |
Non-Māori | 410 (59%) | 88 (47%) |
Age, mean (SD) | 84 (2) | 84 (2) |
Gender, | ||
Men | 312 (45%) | 83 (45%) |
Women | 379 (55%) | 103 (55%) |
Education | ||
- Primary | 146 (21%) | 43 (24%) |
- Secondary | 391 (58%) | 106 (58%) |
- Trade or tertiary | 139 (21%) | 34 (19%) |
NZ Dep Index | ||
- 1 – 4 (low deprivation) | 123 (18%) | 34 (18%) |
- 5—7 | 208 (30%) | 58 (31%) |
- 8—10 | 360 (52%) | 94 (51%) |
Smoking | ||
- Never a smoker | 339 (50%) | 75 (41%) |
- Past (stopped more than 12 mths) | 295 (43%) | 93 (51%) |
- Current | 48 (7%) | 15 (8%) |
Alcohol | ||
- Never | 167 (33%) | 47 (39%) |
- At least monthly | 137 (27%) | 40 (33%) |
- At least twice a week | 208 (41%) | 33 (28%)* |
Number of co-morbidities, median (IQR)* | 5 (3) | 6 (3)** |
Conditions | ||
Diabetes | 141 (20%) | 55 (30%)* |
CVD | 413 (60%) | 167 (90%)** |
Stroke/TIA | 165 (24%) | 65 (35%)** |
CHF | 123 (18%) | 107 (58%)** |
Hypertension | 576 (83%) | 169 (91%)* |
Thyroid disease | 38 (5%) | 11 (6%) |
SBP/DBP, mean (SD) | 152(23) / 81 ((12) | 142 (23) / 80 (14)* |
Fasting glucose (mmol/L), median (IQR) | 5.30 (0.90) | 5.30 (0.70) |
FT4 (pmol/L), median (IQR) | 15.0 (2.6) | 15.8 (3.4)* |
TSH (mIU/L), median (IQR) | 2.5 (2.1) | 3.6 (1.6) |
Total med, median (IQR)* | 5 (5) | 7 (3)** |
BP lowering medication, n (%) | 354 (72%) | 106 (89%)** |
Statin | 179 (37%) | 50 (42%) |
Māori with medication for AF data# | N = 177 | N = 50 |
Aspirin | 84 (48%) | 25 (50%) |
Warfarin | 6 (3%) | 21 (42%) |
Digoxin | 4 (2%) | 15 (30%) |
Aspirin + warfarin | nil | 4 (8%) |
Warfarin or Aspirin | 90 (51%) | 42 (84%) |
Non- Māori with medication for AF data## | n = 316 | N = 66 |
Aspirin | 144 (46%) | 32 (49%) |
Warfarin | 10 (3%) | 33 (50%) |
Digoxin | 5 (2%) | 14 (21%) |
Aspirin + warfarin | 1 (0.3%) | 4 (6%) |
Warfarin or Aspirin | 153 (48%) | 61 (92%) |
Risk scores | ||
CHADS2 median (IQR) | 2 (2) | 3 (1)** |
CHA2DS2-Vas, median (IQR) | 4 (1) | 6 (3)** |
HAS-BLED, median (IQR) | 3 (2) | 3 (2) |
Yearly bleeding risk, n (%) | ||
- 0 to 2 | 259 (37%) | 67 (37%) |
-≥ 3 high risk | 435 (63%) | 116 (63%) |
Falls in the past 12 months | 249 (36%) | 79 (44%) |
Function, NEALD, median (IQR)‡ | 19 (3) | 18 (6)* |
QoL, median (IQR) ‡ | ||
- Mental health related QoL | 57 (10) | 56 (11) |
- Physical health related QoL | 44 (8) | 39 (18)* |
Depressive symptoms, GDS, median (IQR)† | 2 (2) | 2 (3)* |
Cognition, 3MS (adjusted for visual impairment), median (IQR) ‡ | 93 (10) | 92 (10) |